Biomarkers in cancer screening, research and detection: present and future: a review

References

• Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of multitarget assay panel. Gastroenterology 2000; 119: 1219–1227
   PubMed Web of Science ®Google Scholar
• Allan JM, Hardie LJ, Briggs JA, Davidson LA, Watson JP, Pearson SB, Muers MF, Wild CP. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer. International Journal of Cancer 2001; 91: 359–365
   PubMedGoogle Scholar
• Andersen JS, Mann M. Functional genomics by mass spectrometry. FEBS Letters 2000; 480: 25–31
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Molecular Cell Proteomics 2002; 1: 845–867
   PubMed Web of Science ®Google Scholar
• Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L, Pelosi G, Goldstraw P, Sozzi G, Pastorino U. Detecting lung cancer in plasma with the use of multiple genetic markers. International Journal of Cancer 2004; 108: 91–96
   PubMed Web of Science ®Google Scholar
• Arenkov P, Kukhtin A, Gemmell A, Voloshchuk S, Chupeeva V, Mirzabekov A. Protein microchips: use for immunoassay and enzymatic reactions. Annals of Biochemistry 2000; 278: 123–131
   Google Scholar
• Banks RE, Dunn MJ, Hochstrasser DF, Sanchez J-C, Blackstock W, Pappin DJ. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000; 356: 1749–1756
   PubMed Web of Science ®Google Scholar
• Bearzatto A, Conte D, Frattini M, Zaffaroni N, Andriani F, Balestra D, Tavecchio L, Daidone MG, Sozzi G. p16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clinical Cancer Research 2002; 8: 3782–3787
   PubMed Web of Science ®Google Scholar
• Bergman AC, Benjamin T, Alaiya A, Waltham M, Sakaguchi K, Franzen B, Linder S, Bergman T, Auer G, Appella E, Wirth PJ, Jornvall H. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 2000; 21: 679–686
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences, USA 2001; 98: 13790–13795
   PubMed Web of Science ®Google Scholar
• Biomarker Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001; 69: 89–95
   PubMed Web of Science ®Google Scholar
• Blaes F, Klotz M, Huwer H, Straub U, Kalweit G, Schimrigk K, Schafers HJ. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Annals of Thoracic Surgery 2000; 69: 254–258
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer 2005; 49: 1–12
   PubMed Web of Science ®Google Scholar
• Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proceedings of the National Academy of Sciences, USA 2001; 98: 9824–9829
   PubMed Web of Science ®Google Scholar
• Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: a new approach to the study of disease. Journal of Pathology 2000; 192: 280–288
   PubMed Web of Science ®Google Scholar
• Chaurand P, Stoeckli M, Caprioli RM. Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. Annals of Chemistry 1999; 71: 5263–5270
   PubMed Web of Science ®Google Scholar
• Chen CM, Chen HL, Hsiau TH, Hsiau AH, Shi H, Brock GJ, Wei SH, Caldwell CW, Yan PS, Huang TH. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. American Journal of Pathology 2003; 163: 37–45
   PubMedGoogle Scholar
• Chen JJ, Peck K, Hong TM, Yang SC, Sher YP, Shih JY, Wu R, Cheng JL, Roffler SR, Wu CW, Yang PC. Global analysis of gene expression in invasion by a lung cancer model. Cancer Research 2001; 61: 5223–5230
   PubMed Web of Science ®Google Scholar
• De Wildt RMT, Mundy CR, Gorick BD, Tomlinson IM. Antibody arrays for high throughput for screening of antibody–antigen interactions. Nature Biotechnology 2000; 18: 989–994
   PubMed Web of Science ®Google Scholar
• Di Natale C, Macagnano A, Martinelli E, Paolesse R, D'Arcangelo G, Roscioni C, Finazzi-Agro A, D'Amico A. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosensor Bioelectronics 2003; 18: 1209–1218
   PubMed Web of Science ®Google Scholar
• Feng G, Xu X, Youssef EM, Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Research 2001; 61: 7999–8004
   PubMed Web of Science ®Google Scholar
• Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246: 64–71
   PubMed Web of Science ®Google Scholar
• Fernandez-Madrid F, VandeVord PJ, Yang X, Karvonen RL, Simpson PM, Kraut MJ, Granda JL, Tomkiel JE. Antinuclear antibodies as potential markers of lung cancer. Clinical Cancer Research 1999; 5: 1393–1400
   PubMed Web of Science ®Google Scholar
• Fleming R. Barriers to clinical trials. Part I: Reimbursement problems. Cancer 1994; 74: 2662–2665
   PubMed Web of Science ®Google Scholar
• Foley J, Moertel C. Improving accrual into cancer clinical trials. Journal of Cancer Education 1991; 6: 165–173
   PubMedGoogle Scholar
• Geysen HM, Meloen RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proceedings of the National Academy of Sciences, USA 1984; 81: 3998–4002
   PubMed Web of Science ®Google Scholar
• Giardina M, Olesik SV. Application of low-temperature glassy carbon-coated macrofibers for solid-phase microextraction analysis of simulated breath volatiles. Annals of Chemistry 2003; 75: 1604–1614
   PubMed Web of Science ®Google Scholar
• Gilliland FD, Harms HJ, Crowell RE, Li YF, Willink R, Belinsky SA. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum. Cancer Research 2002; 62: 2248–2252
   PubMed Web of Science ®Google Scholar
• Gohagan JK, Srivastava S, Ross SC, Black WC. New screening technologies in cancer screening. Cancer screening theory and practice, BS Kramer, JK Gohagan, PC Prorok. Marcel Dekker, New York, NY 1999; 559–594
   Google Scholar
• Goodman C. Investigational exclusion, clinical trials, and cancer. NCCN Proceedings 1998; 12: 37–49
   Google Scholar
• Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000; 21: 1037–1053
   PubMed Web of Science ®Google Scholar
• Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures by isotope-coded affinity tags. Nature Biotechnology 1999; 17: 994–999
   PubMed Web of Science ®Google Scholar
• Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biology 2001; 2: 1–13
   Google Scholar
• Hanash SM. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 2000; 21: 102–109
   Google Scholar
• Hangai N, Matsunaga H, Hoger JH, Kawamura M, Kobayashi K, Kambara H, Mitsuhashi M. 2000. New lung cancer diagnostic markers from blood. Cancer Detection and Prevention 24 (Suppl. 1):3846.
   Google Scholar
• Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A, Rickert P. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21: 7749–7763
   PubMed Web of Science ®Google Scholar
• Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999; 354: 99–105
   PubMed Web of Science ®Google Scholar
• Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Annals of Chemistry 1991; 63: 1193A–1203A
   Google Scholar
• Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine 2000; 161: 589–594
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Belinski SA, Kennedy TC, Miller YE, Franklin WA, Wolf HJ, Bunn PA, Byers T. Aberrant DNA methylation and sputum atypia predict lung cancer — preliminary report from the university of Colorado SPORE high-risk cohort study. [Abstract]. Proceedings of the American Society of Clinical Oncology 2003; 22: 92
   Google Scholar
• Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Under representation of patients 65 years of age or older in cancer-treatment trials. New England Journal of Medicine 1999; 341: 2061–2067
   PubMed Web of Science ®Google Scholar
• Iizasa T, Fujisawa T, Saitoh Y, Hiroshima K, Ohwada H. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma. Cancer Immunology and Immunotherapy 1998; 46: 345–349
   PubMedGoogle Scholar
• James V, Kearsley J, Irving T, Amemiya Y, Cookson D. Using hair to screen for breast cancer. Nature 1999; 398: 33–34
   PubMed Web of Science ®Google Scholar
• Jr GW, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A. Proteinchip( surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer and Prostatic Disease 1999; 2: 264–276
   PubMedGoogle Scholar
• Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10 000 daltons. Annals of Chemistry 1988; 60: 2299–2301
   PubMed Web of Science ®Google Scholar
• Keohavong P, Gao WM, Zheng KC, Mady H, Lan Q, Melhem M, Mumford J. Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Annals of Biochemistry 2004; 324: 92–99
   Google Scholar
• Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph node metastases and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192–2205
   PubMed Web of Science ®Google Scholar
• Kim WH. Tissue array technology for translational research. From gene discovery to application. Experiments in Molecular Medicine 2001; 33(Suppl. 1)135–148
   PubMedGoogle Scholar
• Kulpa J, Wojcik E, Reinfuss M, Koodziejsk L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clinical Chemistry 2002; 48: 1931–1937
   PubMed Web of Science ®Google Scholar
• Larson RJ, Woloshin S, Schwartz LM, Welch HG. Celebrity endorsements of cancer screening. Journal of the National Cancer Institute 2005; 97: 693–695
   PubMed Web of Science ®Google Scholar
• Laudanski J, Burzykowski T, Niklinska W, Chyczewski K, Furman M, Niklinski J. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer 1998; 22: 191–200
   PubMed Web of Science ®Google Scholar
• Liu Y, An Q, Li L, Zhang D, Huang J, Feng X, Cheng S, Gao Y. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 2003; 24: 1897–1901
   PubMed Web of Science ®Google Scholar
• Mack U, Ukena D, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncology Report 2000; 7: 669–674
   PubMed Web of Science ®Google Scholar
• Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, Gray JW. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implication of the phosphatidylinositol 3-kinase pathway. Cancer Research 2002; 62: 3636–3640
   PubMed Web of Science ®Google Scholar
• McCormack AL, Schieltz DM, Goode B, Yang S, Barnes G, Drubin D, Yates JR 3rd. Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Annals of Chemistry 1997; 69: 767–776
   PubMed Web of Science ®Google Scholar
• Melamed MR. Flow cytometry detection and evaluation of bladder tumors. Journal of Occupational Medicine 1990; 32: 829–833
   PubMedGoogle Scholar
• Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000; 21: 1164–1167
   PubMed Web of Science ®Google Scholar
• Miller AB. Principles of screening and of the evaluation of screening programs. Screening for cancer, A.B Miller. Academic Press, New York, NY 1985; 3–24
   Google Scholar
• Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabara M, Gotoh K, Hatooka S, Shinoda M, Suyama M, Ogawa M, Takahashi T, Ariyoshi Y, Takahashi T. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. Journal of the National Cancer Institute 1998; 90: 1563–1568
   PubMed Web of Science ®Google Scholar
• Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J, Viladiu P. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small-cell lung cancer as an aid in histological diagnosis and prognosis. Tumor Biology 2003; 24: 209–218
   PubMed Web of Science ®Google Scholar
• Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC. Serum protein markers for early detection of ovarian cancer. Proceedings of the National Academy of Sciences, USA 2005; 102: 7677–7682
   PubMed Web of Science ®Google Scholar
• Mulley AG. Health maintenance and the role of screening. Primary care medicine3rd ed, AH Goroll, LA May, AG Mulley. Lippincott, Philadelphia, PA 1995; 13–16
   Google Scholar
• Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Saijo T, Kawasaki N, Kato H. cDNA microarray analysis of gene expression in pathologic stage IA non-small cell lung carcinomas. Cancer 2003; 97: 2798–2805
   PubMed Web of Science ®Google Scholar
• Neri M, Betta P, Marroni P, Filiberti R, Cafferata M, Mereu C, Ivaldi G, Montanaro F, Puntoni R, Paganuzzi M. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. Lung Cancer 2003; 39: 165–172
   PubMedGoogle Scholar
• Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Research 2000; 60: 5954–5958
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin III EF, Liotta LA. Reverse phase protein microarrays, which capture disease progression, show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001a; 20: 1981–1989
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF 3rd. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Disease Markers 2001b; 17: 301–307
   PubMed Web of Science ®Google Scholar
• Peng J, Gygi SP. Proteomics: the move to mixtures. Journal of Mass Spectrometry 2001; 36: 1083–1091
   PubMed Web of Science ®Google Scholar
• Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 2001; 93: 1054–1061
   PubMed Web of Science ®Google Scholar
• Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN. Detection of lung cancer with volatile markers in breath. Chest 2003; 123: 2115–2123
   PubMed Web of Science ®Google Scholar
• Piccoli CW, Rifkin MD. Magnetic resonance imaging of the prostate and bladder. Topics in Magnetic Resonance Imaging 1990; 2: 51–66
   PubMedGoogle Scholar
• Pino I, Pio R, Toledo G, Zabalegui N, Vicent S, Rey N, Lozano MD, Torre W, Garcia-Foncillas J, Montuenga LM. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003; 41: 131–143
   PubMed Web of Science ®Google Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415: 436–442
   PubMed Web of Science ®Google Scholar
• Pulling LC, Divine KK, Klinge DM, Gilliland FD, Kang T, Schwartz AG, Bocklage TJ, Belinsky SA. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Research 2003; 63: 4842–4848
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR. Multiclass cancer diagnosis using tumor gene expression signatures. Proceedings of the National Academy of Sciences, USA 2001; 98: 15149–15154
   PubMed Web of Science ®Google Scholar
• Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL, Margeli M, Sanchez JJ, Astudillo J, Taron M, Rosell R. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Letters 2003; 193: 207–216
   PubMed Web of Science ®Google Scholar
• Report of the National Cancer Institute. Clinal trials program review group. August 26, 1997. ( http://deainfo.nci.gov/advisory/BSA/bsa_program/bsactprgmin.htm).
   Google Scholar
• Rosell R, Monzo M, Sanchez JM, O'Brate A, Nogales E, Guillot M, Sanchez JJ, Aracil C. Beta-tubulin mutations in circulating extracellular DNA of non-small-cell lung cancer (NSCLC) patients (pts.). Proceedings of the American Society of Clinical Oncology 2000; 19: 485
   Google Scholar
• Ross RK, Paganini-Hill A, Henderson HE. Epidemiology of bladder cancer. Diagnosis and management of genitourinary cancer, DG Skinner, G Lieskovsky. W. B. Saunders, Philadelphia, PA 1988; 23–32
   Google Scholar
• Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P. Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997; 18: 599–604
   PubMedGoogle Scholar
• Sher YP, Shih JY, Yang PC, Roffler SR, Chu YW, Wu CW, Yu CL, Peck K. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple-marker genes. Clinical Cancer Research 2005; 11: 173–179
   PubMed Web of Science ®Google Scholar
• Smith JL. Cancer education for the generalist physician. Family Medicine 2001; 33: 371–375
   PubMedGoogle Scholar
• Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society guidelines for the early detection of cancer. A Cancer Journal for Clinicians 2000; 50: 34–49
   PubMed Web of Science ®Google Scholar
• Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J. Maspin — the most commonly expressed gene of the 18q21.3 serpin cluster in lung cancer — is strongly expressed in preneoplastic bronchial lesions. Oncogene 2003; 22: 8677–8687
   PubMedGoogle Scholar
• Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U. Quantification of free circulating DNA as a diagnostic marker in lung cancer. Journal of Clinical Oncology 2003; 21: 3902–3908
   PubMed Web of Science ®Google Scholar
• Stein BS. Advances in the diagnosis and treatment of bladder cancer. Rhode Island Medical Journal 1989; 72: 289–293
   PubMedGoogle Scholar
• Steinberg T, Jones LJ, Haugland RP, Singer VL. SYPRO ruby and SYPRO red protein gel stains. Annals of Biochemistry 1996; 239: 223–237
   Google Scholar
• Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. National Medicine 2001; 7: 493–496
   PubMed Web of Science ®Google Scholar
• Strauss GM, Dominioni L, Jett JR, Freedman M, Grannis FW, Jr. Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference. Chest 2005; 127: 1146–1151
   PubMed Web of Science ®Google Scholar
• Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Research 2002; 62: 3971–3979
   PubMed Web of Science ®Google Scholar
• Taxman DJ, MacKeigan JP, Clements C, Bergstralh DT, Ting JR. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein extracellular signal-regulated kinase inhibitor. Cancer Research 2003; 63: 5095–5104
   PubMed Web of Science ®Google Scholar
• Tominaga M, Sueoka N, Irie K, Iwanaga K, Tokunaga O, Hayashi S, Nakachi K, Sueoka E. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. Lung Cancer 2003; 40: 45–53
   PubMed Web of Science ®Google Scholar
• Tonella L, Walsh BJ, Sanchez JC, Ou K, Wilkins MR, Tyler M, Frutiger S, Gooley AA, Pescaru I, Appel RD, Yan JX, Bairoch A, Hoogland C, Morch FS, Hughes GJ, Williams KL, Hochstrasser DF. ‘98 Escherichia coli SWISS-2DPAGE database update. Electrophoresis 1998; 19: 1960–1971
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force (USPSTF). 2004. Lung cancer screening: recommendation statement. Annals of Internal Medicine 140: 738–739.
   PubMedGoogle Scholar
• Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J, Danenberg PV, Yang S, Sidransky D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Research 2002; 62: 371–375
   PubMed Web of Science ®Google Scholar
• Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304–1351
   PubMed Web of Science ®Google Scholar
• Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, Revillion F, Peyrat JP, Hondermarck H. Proteomic analysis reveals that 14-3-3σ is down regulated in human breast cancer cells. Cancer Research 2001; 61: 76–80
   PubMed Web of Science ®Google Scholar
• Verma M, Kagan J, Sidransky D, Srivastava S. Proteomic analysis of cancer — cell mitochondria. National Reviews in Cancer 2003; 3: 789–795
   PubMed Web of Science ®Google Scholar
• Verma M, Wright GL, Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Annals of the New York Academy of Science, USA 2001; 945: 103–115
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright Jr GL, Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. American Journal of Pathology 2001; 158: 1491–1502
   PubMed Web of Science ®Google Scholar
• Wallace RB. Screening for early and asymptomatic conditions. Public health and preventive medicine14th ed, RB Wallace. Appleton & Lange, Norwalk, CT 1998; 907–8
   Google Scholar
• Wang T, Hopkins D, Schmidt C, Silva S, Houghton R, Takita H, Repasky E, Reed SG. Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene 2000; 19: 1519–1528
   PubMed Web of Science ®Google Scholar
• Whiteside MA, Chen DT, Desmond RA, Addulkadir SA, Johanning GL. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 2004; 23: 744–752
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Sanchez JC, Williams KL, Hochstrrasser DF. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 1996; 17: 830–838
   PubMedGoogle Scholar
• Yagihashi A, Asanuma K, Kobayashi D, Tsuji N, Shijubo Y, Abe S, Hirohashi Y, Torigoe T, Sato N, Watanabe N. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 2005; 48: 217–221
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Patturajan M, Trink B, Usadel H, Koch W, Jen J, Sidransky D. Circulating antibodies to p40 (AIS) in the sera of respiratory tract cancer patients. International Journal of Cancer 2000; 89: 524–528
   PubMedGoogle Scholar
• Yamamoto A, Shimizu E, Ogura T, Sone S. Detection of autoantibodies against L-myc oncogene products in sera from lung cancer patients. International Journal of Cancer 1996; 69: 283–289
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Shimizu E, Takeuchi E, Houchi H, Doi H, Bando H, Ogura T, Sone S. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 1999; 56: 129–133
   PubMed Web of Science ®Google Scholar
• Yates JR III, Carmack E, Hays L, Link AJ, Eng JK. Automated protein identification using microcolumn liquid chromatography-tandem mass spectrometry. Methods in Molecular Biology 1999; 112: 553–569
   PubMedGoogle Scholar
• Yates JR III, McCormack AL, Schieltz D, Carmack E, Link A. Direct analysis of protein mixtures by tandem mass spectrometry. Journal of Protein Chemistry 1997; 16: 495–497
   PubMedGoogle Scholar
• Zhang LF, Gao WM, Gealy R, Weissfeld J, Elder E, Whiteside TL, Keohavong P. Comparison of K-ras gene mutations in tumour and sputum DNA of patients with lung cancer. Biomarkers 2003; 8: 156–161
   PubMed Web of Science ®Google Scholar